Haverford Financial Services Inc. Takes $526,000 Position in Zimmer Biomet (ZBH)

Haverford Financial Services Inc. purchased a new stake in shares of Zimmer Biomet (NYSE:ZBH) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 4,820 shares of the medical equipment provider’s stock, valued at approximately $526,000.

A number of other hedge funds and other institutional investors have also modified their holdings of ZBH. KCM Investment Advisors LLC grew its holdings in shares of Zimmer Biomet by 7.1% in the first quarter. KCM Investment Advisors LLC now owns 33,427 shares of the medical equipment provider’s stock worth $3,645,000 after purchasing an additional 2,205 shares during the last quarter. Envestnet Asset Management Inc. grew its holdings in shares of Zimmer Biomet by 2.6% in the first quarter. Envestnet Asset Management Inc. now owns 29,518 shares of the medical equipment provider’s stock worth $3,262,000 after purchasing an additional 749 shares during the last quarter. Northern Capital Management LLC bought a new position in shares of Zimmer Biomet in the first quarter worth approximately $2,251,000. Afam Capital Inc. grew its holdings in shares of Zimmer Biomet by 1.9% in the first quarter. Afam Capital Inc. now owns 47,181 shares of the medical equipment provider’s stock worth $5,145,000 after purchasing an additional 876 shares during the last quarter. Finally, Thompson Siegel & Walmsley LLC grew its holdings in shares of Zimmer Biomet by 27.8% in the first quarter. Thompson Siegel & Walmsley LLC now owns 721,862 shares of the medical equipment provider’s stock worth $78,711,000 after purchasing an additional 156,997 shares during the last quarter. Institutional investors and hedge funds own 86.45% of the company’s stock.

NYSE:ZBH opened at $115.05 on Friday. The firm has a market capitalization of $23.28 billion, a P/E ratio of 14.33, a P/E/G ratio of 2.24 and a beta of 1.16. Zimmer Biomet has a twelve month low of $111.77 and a twelve month high of $113.83. The company has a current ratio of 1.69, a quick ratio of 1.07 and a debt-to-equity ratio of 0.79.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, April 26th. The medical equipment provider reported $1.91 EPS for the quarter, beating the consensus estimate of $1.89 by $0.02. The business had revenue of $2.02 billion during the quarter, compared to analyst estimates of $1.98 billion. Zimmer Biomet had a return on equity of 14.36% and a net margin of 21.81%. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.13 earnings per share. analysts predict that Zimmer Biomet will post 7.67 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Monday, April 30th. Shareholders of record on Thursday, March 29th were given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.83%. The ex-dividend date of this dividend was Wednesday, March 28th. Zimmer Biomet’s dividend payout ratio is currently 11.96%.

ZBH has been the topic of several recent analyst reports. Citigroup cut their target price on shares of Zimmer Biomet from $132.00 to $121.00 and set a “neutral” rating on the stock in a report on Tuesday, February 27th. ValuEngine cut shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Friday, March 23rd. Morgan Stanley cut their target price on shares of Zimmer Biomet from $150.00 to $148.00 and set an “overweight” rating on the stock in a report on Monday, February 26th. Robert W. Baird cut shares of Zimmer Biomet from an “outperform” rating to a “neutral” rating in a report on Friday, March 23rd. Finally, Evercore ISI initiated coverage on shares of Zimmer Biomet in a report on Monday, April 2nd. They issued an “in-line” rating and a $115.00 target price on the stock. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $137.71.

In other Zimmer Biomet news, VP Tony W. Collins sold 1,330 shares of the firm’s stock in a transaction on Monday, April 30th. The stock was sold at an average price of $116.73, for a total transaction of $155,250.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Bryan C. Hanson acquired 25,077 shares of the stock in a transaction on Tuesday, February 20th. The shares were purchased at an average cost of $119.68 per share, with a total value of $3,001,215.36. The disclosure for this purchase can be found here. Company insiders own 0.71% of the company’s stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Brokerages Set Ameresco Inc  PT at $13.17
Brokerages Set Ameresco Inc PT at $13.17
Brokerages Set Gaia, Inc.  Target Price at $21.50
Brokerages Set Gaia, Inc. Target Price at $21.50
Brokerages Anticipate Chesapeake Energy Co.  Will Announce Earnings of $0.13 Per Share
Brokerages Anticipate Chesapeake Energy Co. Will Announce Earnings of $0.13 Per Share
Safe Exchange Coin  Trading Up 6.8% Over Last 7 Days
Safe Exchange Coin Trading Up 6.8% Over Last 7 Days
NevaCoin  Price Tops $0.0623 on Major Exchanges
NevaCoin Price Tops $0.0623 on Major Exchanges
$1.87 Billion in Sales Expected for American Axle  This Quarter
$1.87 Billion in Sales Expected for American Axle This Quarter


Leave a Reply

© 2006-2018 Ticker Report. Google+.